Tudor Investment Corp ET AL Sells 865,720 Shares of Alignment Healthcare, Inc. $ALHC

Tudor Investment Corp ET AL lowered its position in Alignment Healthcare, Inc. (NASDAQ:ALHC) by 76.0% in the 3rd quarter, HoldingsChannel reports. The fund owned 273,010 shares of the company’s stock after selling 865,720 shares during the period. Tudor Investment Corp ET AL’s holdings in Alignment Healthcare were worth $4,764,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ALHC. Royal Bank of Canada lifted its holdings in Alignment Healthcare by 92.6% during the first quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock valued at $1,720,000 after purchasing an additional 44,413 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Alignment Healthcare by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock valued at $1,109,000 after purchasing an additional 2,594 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Alignment Healthcare by 79.1% in the first quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock valued at $18,112,000 after purchasing an additional 429,703 shares during the period. Woodline Partners LP purchased a new stake in shares of Alignment Healthcare during the 1st quarter valued at approximately $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Alignment Healthcare by 16.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock valued at $5,729,000 after buying an additional 44,452 shares in the last quarter. 86.19% of the stock is currently owned by institutional investors.

Insider Transactions at Alignment Healthcare

In related news, insider Robert L. Scavo sold 69,541 shares of Alignment Healthcare stock in a transaction on Monday, December 29th. The stock was sold at an average price of $18.74, for a total transaction of $1,303,198.34. Following the completion of the sale, the insider owned 503,014 shares of the company’s stock, valued at approximately $9,426,482.36. This trade represents a 12.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John E. Kao sold 605,648 shares of the business’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $18.74, for a total value of $11,349,843.52. Following the transaction, the chief executive officer owned 2,234,294 shares of the company’s stock, valued at approximately $41,870,669.56. The trade was a 21.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 2,418,393 shares of company stock valued at $46,473,667. 7.00% of the stock is currently owned by company insiders.

Alignment Healthcare Price Performance

Shares of NASDAQ:ALHC opened at $17.58 on Thursday. The company has a 50 day moving average of $20.21 and a 200 day moving average of $18.83. The stock has a market cap of $3.59 billion, a P/E ratio of -1,756.24, a P/E/G ratio of 2.55 and a beta of 1.18. Alignment Healthcare, Inc. has a 12 month low of $11.63 and a 12 month high of $23.87. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 1.80.

Alignment Healthcare (NASDAQ:ALHC) last posted its earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.10. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period in the prior year, the company posted ($0.16) EPS. The business’s revenue for the quarter was up 44.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ALHC has been the subject of a number of recent research reports. KeyCorp reiterated an “overweight” rating and issued a $28.00 price objective on shares of Alignment Healthcare in a research note on Thursday, January 22nd. Wall Street Zen downgraded Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. JPMorgan Chase & Co. raised their price target on Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. TD Cowen lifted their price target on Alignment Healthcare from $18.50 to $25.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.56.

Alignment Healthcare Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.